{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:10:16Z","timestamp":1791277816209,"version":"4.1.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/mbc.0b013e328349f1d6","type":"journal-article","created":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T03:14:26Z","timestamp":1318043666000},"page":"637-641","source":"Crossref","is-referenced-by-count":32,"title":["Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban"],"prefix":"10.1097","volume":"22","author":[{"given":"Job","family":"Harenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Giese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1160\/TH09-07-0434","article-title":"New oral anticoagulants in development.","volume":"103","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor.","volume":"30","author":"Perzborn","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"EINSTEIN InvestigatorsOral rivaroxaban for symptomatic venous thromboembolism.","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2008.07.015","article-title":"Determination of rivaroxaban - a novel, oral, direct factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry.","volume":"872","author":"Rohde","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1160\/TH10-03-0204","article-title":"An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.","volume":"104","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban: an oral, direct factor Xa inhibitor.","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"R8-2-20210203","first-page":"64","article-title":"Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy.","volume":"889","author":"van den Besselaar","year":"1999","journal-title":"WHO Tech Rep Ser"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1538-7836.2010.04106.x","article-title":"The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.","volume":"9","author":"Tripodi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0092-1157(86)90018-1","article-title":"The calibration of rabbit tissue thromboplastins: experience of the Dutch Reference Laboratory for anticoagulant control.","volume":"14","author":"van den Besselaar","year":"1986","journal-title":"J Biol Stand"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- 4-(3-oxomorpholin-4-yl)phenyl-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.","volume":"48","author":"Roehrig","year":"2005","journal-title":"J Med Chem"},{"key":"R13-2-20210203","first-page":"89","article-title":"Determination of tissue thromboplastin activity.","volume":"6","author":"Wijngaarts","year":"1977","journal-title":"Haemostasis"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1373\/clinchem.2009.141937","article-title":"Simplified method for international normalized ratio (INR) derivation based on the prothrombin timeINR line: an international study.","volume":"56","author":"Poller","year":"2010","journal-title":"Clin Chem"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1160\/TH09-08-0535","article-title":"INR in liver disease: an ISI derived from liver disease patients improves agreement between INRs with different reagents.","volume":"103","author":"Sermon","year":"2010","journal-title":"Thromb Haemost"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1538-7836.2010.03877.x","article-title":"Reporting prothrombin time results as international normalised ratios for patients with chronic liver disease.","volume":"8","author":"Tripodi","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-0038-1661160","article-title":"A collaborative study designed to establish the 4th International Standard for Heparin.","volume":"52","author":"Thomas","year":"1984","journal-title":"Thromb Haemost"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1055\/s-0038-1660095","article-title":"Standardization of low molecular weight heparins: a collaborative study.","volume":"54","author":"Barrowcliffe","year":"1985","journal-title":"Thromb Haemost"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MBC.0b013e328349f1d6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:31:51Z","timestamp":1786048311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-201112000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e328349f1d6","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}